細胞シグナル伝達の世界市場：現状分析と予測（2022年～2028年）

世界の細胞シグナル伝達の市場規模は、予測期間中に約8.5％のCAGRで成長すると予測されています。慢性疾患の発生率の上昇、細胞ベースの研究機器の技術的進歩、単一細胞解析・体細胞研究・細胞シグナル伝達を含む細胞ベースの研究イニシアチブに対する政府の支援は、市場の成長を促進しています。

当レポートでは、世界の細胞シグナル伝達市場について調査しており、市場の洞察、市場動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場イントロダクション

• 市場の定義
• 主な目標
• ステークホルダー
• 制限

第2章 調査手法または仮定

• 細胞シグナル伝達市場の調査プロセス
• 細胞シグナル伝達市場の調査手法
• 回答者プロファイル

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 COVID-19が細胞シグナル伝達市場に与える影響

第6章 細胞シグナル伝達市場の収益（10億米ドル）（2020年～2028年）

第7章 市場の洞察：製品別

• 消耗品
• 装置

第8章 市場の洞察：タイプ別

• 内分泌シグナル伝達
• 傍分泌シグナル伝達
• 自己分泌シグナル伝達
• 接触分泌シグナル伝達
• その他

第9章 市場の洞察：技術別

• フローサイトメトリー
• ウェスタンブロッティング
• ELISA
• 顕微鏡検査
• その他

第10章 市場の洞察：経路別

• AKTシグナル伝達経路
• AMPKシグナル伝達経路
• ErbB/HERシグナル伝達経路
• その他

第11章 市場の洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋地域
• 世界のその他の地域

第12章 細胞シグナル伝達の市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第13章 細胞シグナル伝達の市場機会

第14章 細胞シグナル伝達の市場動向

第15章 需要側と供給側の分析

• 需要側分析
• 供給側分析

第16章 バリューチェーン分析

第17章 価格分析

第18章 戦略的洞察

第19章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第20章 企業概要

• Abcam plc
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Merck KGaA
• QIAGEN
• BD
• Promega Corporation
• Cell Signaling Technology Inc.
• PerkinElmer Inc.
• Danaher

第21章 免責事項

Cell signaling is the process of cellular communication within the body driven by cells releasing and receiving hormones and other signaling molecules. Cell signaling is a fundamental property of all cellular life in prokaryotes and eukaryotes. Cell signaling is a crucial aspect of biological existence. By enabling cells to sense and react to the extracellular environment, it demonstrates positive benefits that promote growth, development, and immunity. It has several uses in both science and medicine, including the treatment of diabetes, autoimmune, and cancer. The rising incidence of chronic diseases and technological advancements in cell-based research instruments are driving market growth. As per the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), in 2022, Six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes.

The Cell Signaling Market is expected to grow at a steady rate of around 8.5% owing to the availability of funding for cell-based research. Cell-based research initiatives including single-cell analysis, somatic cell research, and cell signaling are being encouraged and supported by the governments of numerous nations. According to the National Institutes of Health (NIH), an estimated USD 45 billion was granted for stem cell research in the fiscal year 2021.

Based on product, the market is segmented into consumables and instruments. The consumables category held a significant market share in 2020. This is mainly due to their augmented implementations in diagnostic and research fields. Moreover, the overview of multiplex probes and reagents for precise applications in diagnostics as well as drug discovery is anticipated to increase the growth opportunities of this segment in research laboratories and small peripheral laboratories.

Based on type, the market is segmented into endocrine signaling, paracrine signaling, autocrine signaling, juxtacrine signaling, and others. Endocrine signaling is expected to grow with a significant CAGR during the forecast period. Almost all of our daily actions are coordinated by the endocrine system, which regulates cell-cell communication. Numerous prevalent disorders, including diabetes, high blood pressure, and obesity, are characterized by abnormalities in hormones, receptors, and cell signaling pathways. d.

On the basis of technology, the market is categorized into flow cytometry, western blotting, ELISA, microscopy, and others. Among these, flow cytometry held a significant market share in 2020. The flow cytometer facilitates the evaluation of physical and chemical characteristics of thousands of particles and is majorly used in the diagnosis of health disorders, such as cancer, HIV AIDS, and immunological disorders.

Based on pathways, the cell signaling market has been classified into AKT signaling pathway, AMPK signaling pathway, ErbB/HER signaling pathway, and others. The AKT signaling pathway is expected to grow with a significant CAGR during the forecast period. AKT pathway promotes the survival and proliferation of tumor cells in many human cancers and metabolism by activating its downstream effectors. According to the World Health Organization, in 2022, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

For a better understanding of the market adoption of the cell signaling market, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the increasing p. The expanding R&D in cell anatomy and physiology is a major driver of this sector's growth. According to the National Bureau of Statistics of China, China's social Research and Experimental Development (R&D) investment in 2021 reached 2.7864 trillion yuan, an increase of 14.2 percent over the previous year. The cell signaling market in the Asia Pacific region is indirectly being supported by robust government initiatives, existing projects, and the availability of funding in rising economies.

Some of the major players operating in the market include: Abcam plc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck KGaA, QIAGEN, BD, Promega Corporation, Cell Signaling Technology Inc., PerkinElmer Inc., Danaher.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Cell Signaling Market
• 2.2. Research Methodology of the Cell Signaling Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CELL SIGNALING MARKET

6 CELL SIGNALING MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY PRODUCT

• 7.1. Consumables
• 7.2. Instruments

8 MARKET INSIGHTS BY TYPE

• 8.1. Endocrine Signaling
• 8.2. Paracrine Signaling
• 8.3. Autocrine Signaling
• 8.4. Juxtacrine Signaling
• 8.5. Others

9 MARKET INSIGHTS BY TECHNOLOGY

• 9.1. Flow Cytometry
• 9.2. Western Blotting
• 9.3. ELISA
• 9.4. Microscopy
• 9.5. Others

10 MARKET INSIGHTS BY PATHWAY

• 10.1. AKT Signaling Pathway
• 10.2. AMPK Signaling Pathway
• 10.3. ErbB/HER Signaling Pathway
• 10.4. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. The U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. The U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 CELL SIGNALING MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 CELL SIGNALING MARKET OPPORTUNITIES

14 CELL SIGNALING MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 PRICING ANALYSIS

18 STRATEGIC INSIGHTS

19 COMPETITIVE SCENARIO

• 19.1. Competitive Landscape
  • 19.1.1. Porters Fiver Forces Analysis

20 COMPANY PROFILED

• 20.1. Abcam plc
• 20.2. Thermo Fisher Scientific Inc.
• 20.3. Bio-Rad Laboratories Inc.
• 20.4. Merck KGaA
• 20.5. QIAGEN
• 20.6. BD
• 20.7. Promega Corporation
• 20.8. Cell Signaling Technology Inc.
• 20.9. PerkinElmer Inc.
• 20.10. Danaher

21 DISCLAIMER